Pfizer/Pharmacia Consumer Product Divestitures Addressing Overlaps – Exec
This article was originally published in The Tan Sheet
Executive Summary
Overlapping consumer product categories appear to be delaying U.S. and EU regulatory approval of Pfizer's acquisition of Pharmacia
You may also be interested in...
Pfizer/Pharmacia merger
Firms reach deal with FTC on divestitures necessary to complete Pfizer's acquisition of Pharmacia, according to March 17 release. Companies further note "they have signed agreements...with buyers for all of the assets to be divested." Pfizer's Rx urinary incontinence drug darifenacin is being divested to Novartis due to Pharmacia's $750 mil. Detrol (tolterodine) franchise. Overlapping consumer brands that could face divestiture include Pharmacia's Dramamine, Pfizer's Bonine motion sickness tablets, which account for more than 70% of the market, and topical anti-itch remedies under Pharmacia's Cortaid, Pfizer's Benadryl, Caladryl, Cortizone lines (1"The Tan Sheet" Jan. 27, 2003, p. 5)...
Pfizer/Pharmacia merger
Firms reach deal with FTC on divestitures necessary to complete Pfizer's acquisition of Pharmacia, according to March 17 release. Companies further note "they have signed agreements...with buyers for all of the assets to be divested." Pfizer's Rx urinary incontinence drug darifenacin is being divested to Novartis due to Pharmacia's $750 mil. Detrol (tolterodine) franchise. Overlapping consumer brands that could face divestiture include Pharmacia's Dramamine, Pfizer's Bonine motion sickness tablets, which account for more than 70% of the market, and topical anti-itch remedies under Pharmacia's Cortaid, Pfizer's Benadryl, Caladryl, Cortizone lines (1"The Tan Sheet" Jan. 27, 2003, p. 5)...
Pfizer/Pharmacia merger
Firms reach deal with FTC on divestitures necessary to complete Pfizer's acquisition of Pharmacia, according to March 17 release. Companies further note "they have signed agreements...with buyers for all of the assets to be divested." Pfizer's Rx urinary incontinence drug darifenacin is being divested to Novartis due to Pharmacia's $750 mil. Detrol (tolterodine) franchise. Overlapping consumer brands that could face divestiture include Pharmacia's Dramamine, Pfizer's Bonine motion sickness tablets, which account for more than 70% of the market, and topical anti-itch remedies under Pharmacia's Cortaid, Pfizer's Benadryl, Caladryl, Cortizone lines (1"The Tan Sheet" Jan. 27, 2003, p. 5)...